Stablepharma Secures £1.7m to Advance Fridge-Free Vaccine Technology at £47m Valuation

Stablepharma Limited, a Bristol-based biopharmaceutical company at the forefront of developing thermostable, fridge-free vaccines and pharmaceutical products, has successfully raised £1.7m in its latest funding round. This capital injection values the innovative firm at an estimated £47m post-money, underscoring investor confidence in its groundbreaking StablevaX™ technology.

Founded on 26 January 2012, Stablepharma addresses a critical global health challenge: the reliance on a complex and often fragile cold chain for vaccine distribution and storage. The World Health Organization (WHO) estimates that approximately 50% of all manufactured vaccines are wasted due to failures within this cold chain, leading to significant financial losses and, more importantly, preventable deaths and disabilities. Stablepharma's core mission is to mitigate this wastage and improve worldwide access to essential medicines by enabling vaccines to be stored for extended periods at room temperature, eliminating the need for refrigeration.

The company's proprietary StablevaX™ technology is designed to create pharmaceutical products that are stable outside of refrigerated conditions. This innovation targets vaccine manufacturers, academic institutions, and global health organizations, offering a solution that not only reduces logistical complexities and costs but also significantly lowers the carbon footprint associated with cold chain maintenance. Stablepharma is actively developing a pipeline of these fridge-free products, including SPVX02, the world's first fridge-free vaccine for Tetanus and Diphtheria prevention. The company's specialties include vaccine stabilisation, improving vaccination programmes, complying with WHO protocols, enhancing vaccine shelf life, reducing CO2 emissions, reducing vaccine wastage, and bolstering pandemic preparedness.

Stablepharma's team, which according to its latest accounts comprises 7 employees, with its LinkedIn profile indicating a broader team of 25, operates from its base in Bristol, though its LinkedIn profile lists Bath, GB, as its headquarters. This dedicated team is focused on bringing its transformative technology to market, aiming to dramatically improve health outcomes for vulnerable populations globally.

This latest funding round, with an estimated size of £1.7m, saw its allotment date on 4 November 2025 and was filed on 29 April 2026. The post-money valuation of £47m represents a continued upward trajectory for the company's financial standing. This round follows a series of successful capital raises that reflect Stablepharma's consistent progress and increasing market value. In December 2024, the company secured £1.7m at a valuation of £41.2m. Prior to that, a £1.4m round in July 2024 valued the company at £39.5m, and a £1.2m raise in December 2023 saw a valuation of £37.3m. An earlier significant round in November 2022 brought in £3.2m at a £33.2m valuation. The company's largest reported round was in September 2019, when it raised £8m at a valuation of £69.6m. The current £1.7m raise, while matching the size of the immediate preceding round, demonstrates a healthy increase in valuation, indicating sustained growth and investor confidence in its long-term potential.

In the broader UK funding landscape, Stablepharma occupies a vital position within the health tech and biotechnology sectors. The development of thermostable vaccines aligns with global priorities for health equity, sustainability, and pandemic preparedness, areas that continue to attract significant investment and strategic interest. The UK has a robust ecosystem for life sciences innovation, and companies like Stablepharma, which are developing solutions with profound global impact, are particularly well-placed to secure funding. Their focus on addressing a fundamental logistical challenge in public health, coupled with the potential for substantial environmental benefits through reduced cold chain emissions, positions Stablepharma as a key player in the evolving landscape of pharmaceutical innovation. The consistent increase in valuation across its recent funding rounds highlights the perceived value of its technology and its potential to disrupt traditional vaccine distribution models, making essential medicines more accessible and reducing waste on a global scale.